Skip to main content
ASTRO 2024 Main banner
Icon Legend
Presentation Icons
Event Add-on
Event Add-on
In Person Only
In Person Only
Off-site Event
Off-site Event
Location: Marriott Marquis
Location: Marriott Marquis
Back
Main Session

EDU 16 - Management of Unfavorable Intermediate-Risk Prostate Cancer: Role of SBRT, Brachytherapy and Androgen Deprivation Therapy

Role of ADT and Genomic Risk Stratification for Patients with Unfavorable Intermediate-Risk Prostate Cancer

Monday, September 30, 2024
8:17 AM – 8:32 AM ET
Location: Room 202

    Speaker(s)

  • Neil Desai, MD

    University of Texas Southwestern Medical Center
    Dallas, TX

Learning Objectives:

  1. Describe the optimal patients with unfavorable intermediate-risk disease who are candidates for prostate SBRT, analyze the appropriate dose of SBRT, and gain comfort in defining the MR-detected lesion(s) to do focal micro-boost to gross disease.
  2. Describe the potential value of EBRT plus brachytherapy boost for unfavorable intermediate-risk vs. brachytherapy without EBRT and to analyze the role of ADT in combination with brachytherapy for unfavorable intermediate-risk disease.
  3. Analyze the role of genomic risk stratification tools to make determinations on the use of ADT as well as the duration of ADT including discussion of the currently accruing NRG GU 010 trial in this disease space.